NewsDialy
The Food and Drug Administration approved a life-extending treatment for advanced pancreatic cancer on Wednesday, the first drug designed to block a genetic driver of the disease.
A genetic driver, in plain terms, is a mutation that acts like a standing order inside cancer cells, telling them to multiply without stopping.
Revolution Medicines, a biotech company, will market the treatment under the brand name Rasonque; the drug's scientific name is daraxonrasib.
Rasonque's approval rested on a clinical trial that produced results earlier this year. The trial enrolled patients who had already gone through one round of therapy that did not work, a setting called second-line.
Keep reading